Figure 1.
Screening and follow-up of patients NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; PFS: progression-free survival; OS: overall survival
Table 1.
Patient characteristics
| Patient characteristics | Total N(%) | EGFR mutations N (%) | Wild type EGFR N (%) | P-value |
|---|---|---|---|---|
| Gender | <0.001 | |||
| Female | 108(45.4%) | 62(57.4%) | 46(42.6%) | |
| Male | 130(54.6%) | 41(31.5%) | 89(68.5%) | |
| Age | 0.308 | |||
| ≥65 | 106(44.5%) | 42(39.6%) | 64(60.4%) | |
| <65 | 132(55.5%) | 61(46.2%) | 71(53.8%) | |
| Smoking history | <0.001 | |||
| Current smoker | 58(25.6%) | 15(25.9%) | 43(74.1%) | |
| Former smoker | 37(16.3%) | 11(29.7%) | 26(70.3%) | |
| Never smoker | 132(58.1%) | 75(56.8%) | 57(43.2%) | |
| Histology types | <0.001 | |||
| Adenocarcinoma | 211(88.7%) | 102(48.3%) | 109(51.7%) | |
| Non-adenocarcinoma | 27(11.3%) | 1(3.7%) | 26(96.3%) | |
| Stage classification | 0.990 | |||
| I-II | 74(31.1%) | 32(43.2%) | 42(56.8%) | |
| IIIA | 7(2.9%) | 3(42.9%) | 4(57.1%) | |
| IIIB | 39(16.4%) | 16(41.0%) | 23(59.0%) | |
| IV | 118(49.6%) | 52(44.1%) | 66(55.9%) |
Table 2.
Mutations detected in exons 18-21 of EGFR
| Exon | EGFR mutation types |
|---|---|
| Exon 18 | G719A; G719C; G719S |
| Exon 19 | E746_A750del (Cosmic ID:6223); E746_T751>A; E746_S752>V; L747_A750>P; L747_E749del; L747_S752del; E746_A750del(Cosmic ID:6225); L747_A750>P; L747_P753>S; L747_T751del; L747_T751>P |
| Exon 20 | T790M; S768I; H773_V774insH; D770_N771insG; V769_D770insASV |
| Exon 21 | L858R; L861Q |
Figure 2.
The contribution of EGFR mutation types
Table 3.
Distribution of exons 18-21
| Patient characteristics | EGFR mutations N (%) | Exon 18 | Exon 19 | Exon 20 | Exon 21 |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 62(60.2%) | 5(83.3%) | 28(56.0%) | 1(50.0%) | 28(60.9%) |
| Male | 41(39.8%) | 1(16.7%) | 22(44.0%) | 1(50.0%) | 18(39.1%) |
| Age | |||||
| >65 | 42(40.8%) | 0(0.0%) | 19(38.0%) | 2(100.0%) | 22(47.8%) |
| ≤65 | 61(59.2%) | 6(100.0%) | 31(62.0%) | 0(0.0%) | 24(52.2%) |
| Smoking status | |||||
| Current smoker | 15(14.9%) | 1(16.7%) | 6(12.5%) | 0(0.0%) | 8(17.4%) |
| Former smoker | 11(10.9%) | 0(0.0%) | 5(10.4%) | 1(50.0%) | 6(13.0%) |
| Never smoker | 75(74.3%) | 5(83.3%) | 37(77.1%) | 1(50.0%) | 32(69.6%) |
| Histology types | |||||
| Adenocarcinoma | 102(99.0%) | 6(100.0%) | 50(100.0%) | 2(100.0%) | 45(97.8%) |
| Non-adenocarcinoma | 1(1.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(2.2%) |
| Stage classification | |||||
| I-II | 32(31.1%) | 2(33.3%) | 17(34.0%) | 0(0.0%) | 13(28.3%) |
| IIIA | 3(2.9%) | 0(0.0%) | 2(4.0%) | 0(0.0%) | 1(2.2%) |
| IIIB | 16(15.5%) | 1(16.7%) | 8(16.0%) | 0(0.0%) | 7(15.2%) |
| IV | 52(50.5%) | 3(50.0%) | 23(46.0%) | 2(100.0%) | 25(54.3%) |
Table 4.
Univariate analysis and multivariate logistic regression analysis for EGFR mutations
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| P-value | OR | 95% CI | P-value | ||
| Gendera | <0.001 | ||||
| Male | 1 | References | |||
| Female | 1.35 | 0.57-3.19 | 0.498 | ||
| Age | 0.308 | ||||
| >65 | |||||
| ≤65 | |||||
| Smoking statusa | <0.001 | ||||
| Current smoker | 1 | References | |||
| Former smoker | 1.32 | 0.51-3.41 | 0.568 | ||
| Never smoker | 2.76 | 1.04-7.34 | 0.042 | ||
| Histology typesa | <0.001 | ||||
| Non-adenocarcinoma | 1 | References | |||
| Adenocarcinoma | 17.07 | 2.21-132.04 | 0.007 | ||
| Stage classification | 0.990 | ||||
| I-II | |||||
| IIIA | |||||
| IIIB | |||||
| IV | |||||
Figure 3.
Kaplan - Meier curve of progression-free survival (A) and overall survival (B) in advanced NSCLC patients with EGFR mutations or wild type EGFR.